REDHILL BIOPHARMA LTD-OPAGANIB AS HOST-DIRECTED THERAPEUTIC FOR EBOLA VIRUS DISEASE
- Funded by Biomedical Advanced Research and Development Authority (BARDA)
- Total publications:0 publications
Grant number: 75A50124C00059
Grant search
Key facts
Disease
EbolaStart & end year
20242025Known Financial Commitments (USD)
$733,381.75Funder
Biomedical Advanced Research and Development Authority (BARDA)Research Location
IsraelLead Research Institution
REDHILL BIOPHARMA LTDResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
Pre-clinical studiesSpecial Interest Tags
N/AStudy Type
Non-ClinicalClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
REDHILL BIOPHARMA LTD-OPAGANIB AS HOST-DIRECTED THERAPEUTIC FOR EBOLA VIRUS DISEASE